FAP positive fibroblasts induce immune checkpoint blockade resistance in colorectal cancer via promoting immunosuppression

Biochemical and Biophysical Research Communications

Volumn 487, Issue 1, 2017, Pages 8-14

  Chen, Lingling ^a   Qiu, Xiangting ^a   Wang, Xinhua ^a   He, Jian ^a  

^a LINYI CENTRAL HOSPITAL   (China)

Author keywords

Cancer associated fibroblast; CCL2; Colorectal cancer; Fibroblast activation protein alpha; Immune checkpoint blockade

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; CXCL1 CHEMOKINE; CXCL2 CHEMOKINE; GRANZYME B; INTERLEUKIN 12; INTERLEUKIN 16; INTERLEUKIN 2; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; PROGRAMMED DEATH 1 LIGAND 1; RANTES; SEPRASE; GELATINASE; MEMBRANE PROTEIN; SERINE PROTEINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW CELL; CANCER IMMUNOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; UPREGULATION; ANIMAL; COLORECTAL TUMOR; FIBROBLAST; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; INNATE IMMUNITY; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; FIBROBLASTS; GELATINASES; IMMUNE TOLERANCE; IMMUNITY, INNATE; MEMBRANE PROTEINS; MICE; SERINE ENDOPEPTIDASES;

EID: 85017451803     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2017.03.039     Document Type: Article

References (22)

1. [1] Torre, L.A., Bray, F., Siegel, R.L., Ferlay, J., Lortet-Tieulent, J., Jemal, A., Global cancer statistics, 2012. Epub 2015/02/06 CA Cancer J. Clin. 65:2 (2015), 87–108, 10.3322/caac.21262 PubMed PMID: 25651787.
2. [2] Marmol, I., Sanchez-de-Diego, C., Pradilla Dieste, A., Cerrada, E., Rodriguez Yoldi, M.J., Colorectal carcinoma: a general overview and future perspectives in colorectal cancer. Int. J. Mol. Sci., 18(1), 2017, 10.3390/ijms18010197 PubMed PMID: 28106826.
3. [3] Koliaraki, V., Pallangyo, C.K., Greten, F.R., Kollias, G., Mesenchymal cells in colon cancer. Gastroenterology, 2017, 10.1053/j.gastro.2016.11.049 PubMed PMID: 28111227.
4. [4] Kuzet, S.E., Gaggioli, C., Fibroblast activation in cancer: when seed fertilizes soil. Cell Tissue Res. 365:3 (2016), 607–619, 10.1007/s00441-016-2467-x PubMed PMID: 27474009.
5. [5] Lim, H., Moon, A., Inflammatory fibroblasts in cancer. Arch. Pharm. Res. 39:8 (2016), 1021–1031, 10.1007/s12272-016-0787-8 PubMed PMID: 27384063.
6. [6] Errarte, P., Guarch, R., Pulido, R., Blanco, L., Nunes-Xavier, C.E., Beitia, M., et al. The expression of fibroblast activation protein in clear cell renal cell carcinomas is associated with synchronous lymph node metastases. PLoS One, 11(12), 2016, e0169105, 10.1371/journal.pone.0169105 PubMed PMID: 28033421; PubMed Central PMCID: PMCPMC5199084.
7. [7] Tyulkina, D.V., Pleshkan, V.V., Alekseenko, I.V., Kopantseva, M.R., Sverdlov, E.D., Expression of the FAP gene in non-fibroblast human cell lines. Development of cancer-associated fibroblast models. Dokl. Biochem. Biophys. 470:1 (2016), 319–321, 10.1134/S1607672916050033 PubMed PMID: 27817025.
8. [8] Xia, Q., Geng, F., Zhang, F.F., Liu, C.L., Xu, P., Lu, Z.Z., et al. Cyclophosphamide enhances anti-tumor effects of a fibroblast activation protein alpha-based DNA vaccine in tumor-bearing mice with murine breast carcinoma. Immunopharmacol. Immunotoxicol. 39:1 (2017), 37–44, 10.1080/08923973.2016.1269337 PubMed PMID: 28004985.
9. [9] Wen, X., Xie, Y., He, X., Jiao, F., Wang, C., Sun, Y., et al. Fibroblast activation protein-alpha positive fibroblasts promote gastric cancer progression and resistant to immune checkpoint blockade. Oncol. Res., 2016, 10.3727/096504016X14768383625385 PubMed PMID: 27983931.
10. [10] Yang, X., Lin, Y., Shi, Y., Li, B., Liu, W., Yin, W., et al. FAP promotes immunosuppression by cancer-associated fibroblasts in the tumor microenvironment via STAT3-CCL2 signaling. Cancer Res. 76:14 (2016), 4124–4135, 10.1158/0008-5472.CAN-15-2973 PubMed PMID: 27216177.
11. [11] Henry, L.R., Lee, H.O., Lee, J.S., Klein-Szanto, A., Watts, P., Ross, E.A., et al. Clinical implications of fibroblast activation protein in patients with colon cancer. Epub 2007/03/17 Clin. Cancer Res. 13:6 (2007), 1736–1741, 10.1158/1078-0432.ccr-06-1746 PubMed PMID: 17363526.
12. [12] Singh, P.P., Sharma, P.K., Krishnan, G., Lockhart, A.C., Immune checkpoints and immunotherapy for colorectal cancer. Epub 2015/10/30 Gastroenterol. Rep. (Oxf) 3:4 (2015), 289–297, 10.1093/gastro/gov053 PubMed PMID: 26510455; PubMed Central PMCID: PMCPMC4650981.
13. [13] Erez, N., Truitt, M., Olson, P., Arron, S.T., Hanahan, D., Cancer-associated fibroblasts are activated in Incipient neoplasia to orchestrate tumor-promoting inflammation in an NF-kappaB-dependent manner. Cancer Cell. 17:2 (2010), 135–147, 10.1016/j.ccr.2009.12.041 PubMed PMID: 20138012.
14. [14] Jansen, K., Heirbaut, L., Cheng, J.D., Joossens, J., Ryabtsova, O., Cos, P., et al. Selective inhibitors of fibroblast activation protein (FAP) with a (4-Quinolinoyl)-glycyl-2-cyanopyrrolidine scaffold. Epub 2014/06/06 ACS Med. Chem. Lett. 4:5 (2013), 491–496, 10.1021/ml300410d PubMed PMID: 24900696; PubMed Central PMCID: PMCPMC4027141.
15. [15] Park, J., Kwon, M., Shin, E.C., Immune checkpoint inhibitors for cancer treatment. Arch. Pharm. Res. 39:11 (2016), 1577–1587, 10.1007/s12272-016-0850-5 PubMed PMID: 27770382.
16. [16] Zhao, X., Subramanian, S., Intrinsic resistance of solid tumors to immune checkpoint blockade therapy. Cancer Res., 2017, 10.1158/0008-5472.CAN-16-2379 PubMed PMID: 28159861.
17. [17] Chen, J., Ye, Y., Liu, P., Yu, W., Wei, F., Li, H., et al. Suppression of T cells by myeloid-derived suppressor cells in cancer. Epub 2016/12/13 Hum. Immunol. 78:2 (2017), 113–119, 10.1016/j.humimm.2016.12.001 PubMed PMID: 27939507.
18. [18] Ku, A.W., Muhitch, J.B., Powers, C.A., Diehl, M., Kim, M., Fisher, D.T., et al. Tumor-induced MDSC act via remote control to inhibit L-selectin-dependent adaptive immunity in lymph nodes. Elife, 2016, 5, 10.7554/eLife.17375 PubMed PMID: 27929373; PubMed Central PMCID: PMCPMC5199197.
19. [19] Zhang, C., Wang, S., Yang, C., Rong, R., The crosstalk between myeloid derived suppressor cells and immune cells: to establish immune tolerance in transplantation. 2016:4986797. Epub 2016/11/22 J. Immunol. Res., 2016, 10.1155/2016/4986797 PubMed PMID: 27868073.
20. [20] Xu, M., Zhao, Z., Song, J., Lan, X., Lu, S., Chen, M., et al. Interactions between interleukin-6 and myeloid-derived suppressor cells drive the chemoresistant phenotype of hepatocellular cancer. Epub 2017/01/23 Exp. Cell Res., 2017, 10.1016/j.yexcr.2017.01.008 PubMed PMID: 28109867.
21. [21] Malek, E., de Lima, M., Letterio, J.J., Kim, B.G., Finke, J.H., Driscoll, J.J., et al. Myeloid-derived suppressor cells: the green light for myeloma immune escape. Blood Rev. 30:5 (2016), 341–348, 10.1016/j.blre.2016.04.002 PubMed PMID: 27132116.
22. [22] Chang, A.L., Miska, J., Wainwright, D.A., Dey, M., Rivetta, C.V., Yu, D., et al. CCL2 produced by the glioma microenvironment is essential for the recruitment of regulatory T cells and myeloid-derived suppressor cells. Epub 2016/08/18 Cancer Res. 76:19 (2016), 5671–5682, 10.1158/0008-5472.can-16-0144 PubMed PMID: 27530322; PubMed Central PMCID: PMCPMC5050119.